Nucletron will show the AccuBoost system with the microSelectron high-dose rate (HDR) brachytherapy afterloader treatment delivery solution for the treatment of breast cancer. The partnership will enable clinicians to deliver boost brachytherapy as part of the whole breast irradiation procedure.
Developed in ollaboration with Advanced Radiation Therapy (ART), the sytem offers radiation oncology centers the opportunity to implement ART's innovative technology in image-guided HDR breast brachytherapy on a pay-per-patient pricing model, along with a full complement of Nucletron's treatment planning, treatment delivery, training, licensing, reimbursement, and customized service support.
ART’s expansion of AccuBoost technology through its global partnership with Nucletron aims to reduce the barriers to adoption of brachytherapy for cancer centers previously deterred by the initial start-up costs usually associated with implementing a breast brachytherapy program.
Clinical reports indicate that patients with early stage breast cancer have the best outcomes when the breast conserving lumpectomy procedure is combined with a full course of whole breast irradiation and partial breast boost dose. ART's AccuBoost combines a mammography procedure for real-time image guidance to target the boost dose, and dose delivery by Nucletron’s microSelectron family of HDR afterloaders.
February 15, 2024 
